Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 486 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizo-Affective Disorder Clear all
Completed Phase 4 Interventional Results available

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NCT01981759
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 68 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

Cognitive Therapy for Negative Symptoms and Functioning

NCT00350883
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Therapy, Treatment as Usual
Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

NCT00421954
View directory record Official record
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 4 Interventional

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Minnesota Community-Based Cognitive Training in Early Psychosis

NCT03079024
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions
Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Stimulating the Brain to Improve Self-Awareness

NCT03370341
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
active anodal tDCS, sham tDCS
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI

NCT02334280
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
In SHAPE
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Lebanon, New Hampshire • Manchester, New Hampshire • Nashua, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program

NCT03005574
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
TSW-HP, TSW-T
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 4 Interventional

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

NCT00391261
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

NCT00690274
View directory record Official record
Conditions
Schizophrenia
Interventions
BF2.649, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2Phase 3 Interventional

Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia

NCT00430560
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
cognitive rehabilitation, work therapy, work therapy
Behavioral · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Exercise and Cognitive Training

NCT02326389
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Exercise, Cognitive Remediation
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 1 Interventional

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02055287
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LY03004
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Orange, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

NCT01487668
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Jul 22, 2026, 2:25 PM EDT
Terminated Not applicable Interventional Results available

Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

NCT03648268
View directory record Official record
Conditions
Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
Interventions
repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Improving Antipsychotic Adherence Among Patients With Serious Mental Illness

NCT00057135
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Unit of use medication packaging, Mailed reminders to patient when medication refills are due, Note to Mental Health Provider when refill is overdue, Aligning all prescriptions to fall due on same date
Behavioral · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
San Diego, California • Hines, Illinois • East Orange, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 1 Interventional Results available

Nonconvulsive Electrotherapy: a Proof-of-concept Trial

NCT01065597
View directory record Official record
Conditions
Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
Interventions
Nonconvulsive electrotherapy
Device
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT00498550
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Abuse
Interventions
Clozapine, Treatment as usual
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Kansas City, Missouri • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View directory record Official record
Conditions
Patient Noncompliance
Interventions
haloperidol decanoate, haloperidol, Customized Adherence Enhancement
Drug · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Jul 22, 2026, 2:25 PM EDT
Recruiting Not applicable Interventional

Cognitive Training for Emotion Regulation in Psychotic Disorders

NCT04414215
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Emotional working memory training, Placebo working memory training
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)

NCT00119574
View directory record Official record
Conditions
Schizophrenia Disorders, Chronic Illness, Schizoaffective Disorder, Weight Gain
Interventions
Collaborative Chronic Illness Model
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Artemisinin to Reduce The Symptoms of Schizophrenia

NCT00753506
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Artemisinin, Identical looking placebo capsule
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 22, 2026, 2:25 PM EDT